DTG/ABC/3TC — Competitive Intelligence Brief

DTG/ABC/3TC (DTG/ABC/3TC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

DTG/ABC/3TC (DTG/ABC/3TC) — Harvard School of Public Health (HSPH). This is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DTG/ABC/3TC TARGET	DTG/ABC/3TC	Harvard School of Public Health (HSPH)	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir and Abacavir/Lamivudine	Raltegravir and Abacavir/Lamivudine	Denver Infectious Disease Consultants, PLLC	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
dolutegravir/abacavir/lamivudine	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Central Institute of Epidemiology, Moscow, Russia · 1 drug in this class
2. Harvard School of Public Health (HSPH) · 1 drug in this class
3. Juan A. Arnaiz · 1 drug in this class
4. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
5. Prism Health North Texas · 1 drug in this class